- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:54 | Biogen's salanersen gets FDA Breakthrough Therapy Designation for SMA | 3 | PMLiVE | ||
| 14:51 | Opening Bell: Bitcoin, Strategy, Broadcom, Marvell, Micron, Axon Enterprise, Moderna, Lululemon | 196 | Der Aktionär TV | Die US-Börsen haben am Donnerstag eine zweigeteilte Entwicklung gezeigt. Der Dow Jones eröffnete mit klaren Gewinnen, baute diese im Verlauf deutlich aus und schloss 1,73 Prozent fester. Der Nasdaq... ► Artikel lesen | |
| 14:46 | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14:42 | Ainos highlights third-party report on AI Nose expansion | 1 | Investing.com | ||
| 14:42 | Amneal reports interim data on Parkinson's drug CREXONT | 1 | Investing.com | ||
| 14:42 | Amneal reports interim data for Parkinson's drug CREXONT | 2 | Investing.com | ||
| 14:42 | BioCardia receives FDA feedback on heart failure trial pathway | 1 | Investing.com | ||
| 14:39 | Aptahem to Participate at IOPC 2026 in Athens | 2 | Cision News | ||
| 14:36 | Moleculin Biotech, Inc.: Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML | 2 | GlobeNewswire (USA) | ||
| 14:34 | VASRO-Bericht: Ainos' KI-Nase expandiert in den Gesundheitssektor | 2 | Investing.com Deutsch | ||
| 14:34 | BioCardia: FDA bestätigt potenziellen Zulassungsweg für Herzinsuffizienz-Therapie | 1 | Investing.com Deutsch | ||
| 14:30 | Moleculin Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14:28 | Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now) | 1 | The Motley Fool | ||
| 14:15 | CRISPR Therapeutics AG - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14:10 | PMV Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14:06 | Amneal Pharmaceuticals, Inc.: Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 14:06 | UroGen Pharma Ltd.: UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14:06 | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 6 | GlobeNewswire (USA) | ||
| 14:06 | BioCardia, Inc.: FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF | 1 | GlobeNewswire (USA) | ||
| 14:02 | Ainos, Inc.: VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations | 185 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence... ► Artikel lesen |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| EVOTEC | 5 | 44 | -0,88 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | ||
| LIQUIDIA | 5 | 1 | +0,26 % | H.C. Wainwright hebt Kursziel für Liquidia wegen Rechtsaussichten auf 75 $ an | |||
| FARON PHARMACEUTICALS | 5 | - | +0,80 % | Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee | TURKU, FI / ACCESS Newswire / June 5, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies... ► Artikel lesen | ||
| GRAIL | 5 | - | +1,26 % | GRAIL, Inc.: GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting | The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the... ► Artikel lesen | ||
| BIONTECH | 4 | 13 | -1,92 % | BioNTech SE: Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs | Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs... ► Artikel lesen | ||
 | LAKEFRONT BIOTHERAPEUTICS | 4 | 2 | +0,58 % | Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline | - Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases -
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront... ► Artikel lesen | |
| VERICI DX | 4 | - | 0,00 % | Verici Dx will 2,5 Mio. Pfund für Expansion bei Transplantationstests einwerben | |||
| CLIMB BIO | 4 | - | +0,28 % | Climb Bio meldet erste Sicherheitsdaten für CLYM116 in IgAN-Studie | |||
 | BIODLINK INTERNATIONAL | 4 | - | - | BIODLINK-B (01875): FORM OF PROXY | ||
| REGENERON PHARMACEUTICALS | 3 | 22 | -0,24 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| BIO-GATE AG | 0,710 | 3,40 | +379 % | 1 | - | - | |||
| DARWIN AG | 6,350 | 24,75 | +290 % | 2 | - | - | |||
| NANOREPRO AG | 1,785 | 4,50 | +152 % | 2 | - | - | |||
| EVOTEC SE | 5,070 | 8,07 | +59 % | 7 | 3 | - | |||
| BIONTECH SE ADR | 76,60 | 117,78 | +54 % | 9 | - | - | |||
| SARTORIUS STEDIM BIOTECH SA | 184,20 | 232,14 | +26 % | 12 | 2 | - | |||
| ARGENX SE | 730,00 | 844,25 | +16 % | 15 | 2 | - | |||
| MODERNA INC | 43,855 | 38,28 | -13 % | - | 1 | - |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.